This is a contrast between Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) and INSYS Therapeutics Inc. (NASDAQ:INSY) based on their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Earnings and Valuation
Demonstrates Can-Fite BioPharma Ltd. and INSYS Therapeutics Inc. earnings per share (EPS), gross revenue and valuation.
Table 2 shows us Can-Fite BioPharma Ltd. and INSYS Therapeutics Inc.’s return on assets, net margins and return on equity.
The table delivered features the ratings and recommendations for Can-Fite BioPharma Ltd. and INSYS Therapeutics Inc.
INSYS Therapeutics Inc. on the other hand boasts of a $7.75 consensus target price and a 832.27% potential upside.
Institutional Insider Ownership
Roughly 23.43% of Can-Fite BioPharma Ltd. shares are held by institutional investors while 18.9% of INSYS Therapeutics Inc.